By Doug Macron
This article has been updated to include comments from Quark's CEO.
Quark Pharmaceuticals expects to file an investigational new drug application for its siRNA-based eye-disease treatment QPI-1007 sometime in September, RNAi News has learned.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
